Human A Disintegrin And Metalloprotease 10,ADAM10 ELISA Kit

Code CSB-E11172h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
ADAM metallopeptidase domain 10
Alternative Names
ADAM10; KUZ; MADM; Disintegrin and metalloproteinase domain-containing protein 10; ADAM 10; CDw156; Kuzbanian protein homolog; Mammalian disintegrin-metalloprotease; CD antigen CD156c
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
7.8 pg/mL-500 pg/mL
1.95 pg/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
To assess the linearity of the assay, samples were spiked with high concentrations of human ADAM10 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 92  
Range % 87-96  
1:2 Average % 106  
Range % 98-109  
1:4 Average % 92  
Range % 88-95  
1:8 Average % 96  
Range % 90-101  
The recovery of human ADAM10 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 90 84-94  
EDTA plasma (n=4) 94 90-98  
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected  
500 2.053 1.981 2.017 1.918  
250 1.568 1.545 1.557 1.458  
125 0.823 0.811 0.817 0.718  
62.5 0.420 0.444 0.432 0.333  
31.2 0.273 0.285 0.279 0.180  
15.6 0.178 0.182 0.180 0.081  
7.8 0.127 0.131 0.129 0.030  
0 0.098 0.100 0.099    
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

The ELISA Kit is designed for quantitatively measuring human ADAM10 levels in samples, including serum, plasma, or tissue homogenates. It uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of ADAM10 in samples. The color intensity is measured at 450 nm via a microplate reader.

ADAM10, a member of the large family of ADAMs, is expressed at high levels in the brain and modulates the molecular organization and activity of the excitatory synapse by shedding postsynaptic proteins, including N-cadherin (N-CAD), amyloid precursor protein, nectin-1, prion protein, neuroligin-1, neural cell adhesion molecule L1, and ephrin A2 and A5. ADAM10-mediated shedding of cell-adhesion molecules at the synapse activates a number of processes critical to the proper formation, maintenance, and function of the excitatory synaptic circuitries. ADAM10 is essential for development because it cleaves Notch proteins to induce Notch signaling and regulate cell fate decisions. Impairments in ADAM10 level and/or activity are detrimental to the human brain. ADAM10 has been associated with epilepsy, Alzheimer's disease, and the developmental disorder Fragile X syndrome.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. Mediates the proteolytic cleavage of IL6R and IL11RA, leading to the release of secreted forms of IL6R and IL11RA. Enhances the cleavage of CHL1 by BACE1. Cleaves NRCAM. Cleaves TREM2, resulting in shedding of the TREM2 ectodomain. Involved in the development and maturation of glomerular and coronary vasculature. During development of the cochlear organ of Corti, promotes pillar cell separation by forming a ternary complex with CADH1 and EPHA4 and cleaving CADH1 at adherens junctions. May regulate the EFNA5-EPHA3 signaling.; (Microbial infection) Promotes the cytotoxic activity of S.aureus hly by binding to the toxin at zonula adherens and promoting formation of toxin pores.
Gene References into Functions
  1. SNHG20 could function as an oncogenic long non-coding RNA by regulating miR-140-5p-ADAM10 axis and MEK/ERK signaling pathway in cervical cancer. PMID: 29604594
  2. restoration of ADAM10 expression partially reversed the effects of miR152 on cell proliferation and apoptosis in rheumatoid arthritisfibroblastlike synoviocytes. PMID: 29693139
  3. Mechanisms underlying ADAM10 downregulation by miR-140-5p and suggests that dysfunctional regulation of ADAM10 expression is exacerbated by AD-related neurotoxic effects. PMID: 29253717
  4. elevated expression of ADAM10 was associated with the pathogenesis and development of immune thrombocytopenia PMID: 29223855
  5. Report overexpression of ADAM10 in oral squamous cell carcinomas, especially in OSCC with metastasis. PMID: 29895129
  6. High ADAM10 expression is associated with meningococcal purpura fulminans. PMID: 29630665
  7. The findings of the present study suggested that miR320a may function as a tumor suppressor in GC progression and potential therapeutic strategies for GC may be based on the miR320a/ADAM10 axis. PMID: 29152656
  8. Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17. PMID: 28819788
  9. mechanistic experiments revealed that ADAM10-RNAi resulted in an increase in E-cadherin and a decrease in N-cadherin and vimentin expression. Our study implies that high expression of ADAM10 promotes the proliferation and migration of hypopharyngeal squamous cell carcinoma (HSCC). These findings may help to provide a method for treatment of HSCC PMID: 28656294
  10. Notch is ligand activated and undergoes DTX4-mediated ubiquitylation and bilateral endocytosis before ADAM10 processing PMID: 28611181
  11. therapies against ADAM10 and ADAM17 may promote cancer stem cell migration away from the tumourigenic niche resulting in a differentiated phenotype that is more susceptible to treatment. PMID: 27541285
  12. Presence of anti-ADAM10 auto-Antibodies seems to reflect the increased tumor expression of the immunogenic immature-ADAM10 in a group of Colorectal cancer patients, and is associated with a favourable prognosis in patients at stage III of the disease. PMID: 27517630
  13. ADAM10 and ADAM17 are the best characterized members of the ADAM (A Disintegrin and Metalloproteinase) - family of transmembrane proteases. Both are involved diverse physiological and pathophysiological processes.For ADAM17 phosphatidylserine exposure is required to then induce its shedding function. PMID: 28624437
  14. A better understanding of the regulatory mechanisms controlling the expression, subcellular localization and activity of ADAM10 will likely uncover suitable drug targets which will allow a more specific and fine-tuned modulation of its proteolytic activity PMID: 28624438
  15. In the present study, the authors show that deletion of a triple serine (3S) motif (Ser-359 to Ser-361) adjacent to the cleavage site is sufficient to prevent IL-6R cleavage by ADAM17, but not ADAM10. We find that the impaired shedding is caused by the reduced distance between the cleavage site and the plasma membrane. PMID: 27151651
  16. Here, I review some of the proposed functions of ADAM10 associated with intestinal crypt homeostasis and tumorigenesis within the gastrointestinal tract in vivo. PMID: 28739265
  17. Study reports the structure of the ADAM10 ectodomain, providing fundamental insights into how substrate selectivity and regulation of catalytic activity is achieved in this important representative of the ADAM family of metalloproteases. PMID: 29224781
  18. Data suggest that ADAM10 associates directly with all members of a subgroup of tetraspanins having eight cysteines in the large extracellular domain ('TspanC8'): Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and Tspan33. [REVIEW] PMID: 28687716
  19. Results found ADAM10 expression under the regulation of MIR-655 which binds the 3'-UTR of ADAM10 mediating the progression of hepatocellular carcinoma. PMID: 27259866
  20. Data suggest that activation of the metalloproteinase ADAM10 by signal peptide peptidase-like 3 (SPPL3) triggered by mutant BRAF(V600E) was a critical transformation event. PMID: 28292959
  21. The ADAM17 messenger RNA (mRNA) and protein levels were significantly higher in the inferior turbinate than in nasal polyps (p < 0.05). The ADAM10 mRNA and protein levels did not differ significantly between NPs and inferior turbinates (p > 0.05). ADAM10 and ADAM17 were expressed primarily in inflammatory cells, submucosal glandular cells, and lining epithelial cells. PMID: 27012683
  22. study confirms the importance of ICOSL shedding in ICOS/ICOSL function and expression and it identifies ADAM10 as the most important sheddase for controlling ICOSL levels PMID: 28814605
  23. Inhibition of ADAM10 suppressed the expansion of NK cells and reduced the expression of CD16. PMID: 28982863
  24. Platelet ADAM10 protein expression in patients with AD [Alzheimer's Disease] was positively influenced by serotoninergic medication PMID: 26555131
  25. Tspan3 is a central endocytic membrane component regulating the expression of ADAM10, presenilin and the amyloid precursor protein. PMID: 27818272
  26. Endothelial Tspan5- and Tspan17-ADAM10 complexes may regulate inflammation by maintaining normal VE-cadherin expression and promoting T lymphocyte transmigration. PMID: 28600292
  27. Regulation of ADAM10 by the TspanC8 subgroup of tetraspanins, namely Tspan5, 10, 14, 15, 17 and 33 is reviewed. PMID: 28620033
  28. active ADAM10 form marks cancer stem-like cells with active Notch signaling, known to mediate chemoresistance. PMID: 27503072
  29. Data show that tetraspanin 33 (tspan33) is an early activation marker, and that disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) protein expression does not correlate with Tspan33 expression in B cells. PMID: 28449222
  30. High ADAM10 expression is associated with metastasis of hepatocellular carcinoma. PMID: 28184920
  31. The dysregulation of ADAM10, Fas and FasL could be useful indicators of the progression and severity of OSCC. PMID: 27628319
  32. 1,25D3 causes ectodomain shedding of TLR4 and thereby decreases the responsiveness of cells to LPS. ADAM10, activated by extracellular Ca2+ influx, was implicated in the ectodomain cleavage of TLR4. PMID: 28427048
  33. The overexpression of MTERF4 induced a significant increase in the levels of APP protein and secreted Abeta 42 in HEK293-APPswe cells compared with control cells these results suggest that MTERF4 promotes the amyloidogenic processing of APP by inhibiting ADAM10 in HEK293-APPswe cells; therefore, MTERF4 may play an important role in the pathogenesis of Alzheimer's disease. PMID: 27894840
  34. Pre-incubation with simvastatin prior to treatment with IL-1beta + Oncostatin M decreased the level of CD44 fragmentation, decreased the proportion of CD44 that transits into the lipid raft fractions, decreased ADAM10 activity and diminished the interaction between CD44 and ADAM10. PMID: 27242325
  35. ADAM17 and ADAM10 cleave Nectin-4 and release soluble Nectin-4 (sN4). PMID: 28232483
  36. Data show that mononuclear leukocytes (PBMC) AXL receptor tyrosine kinase (Axl) is rescued by combined matrix metalloproteases ADAM10 and TACE (ADAM17) inhibition. PMID: 27237127
  37. we found that ADAM10 expression was associated with a more rapid metastatic progression confirming its role in uveal melanoma metastasis. PMID: 27546281
  38. the TLR4/Gal-1 signaling pathway regulates lactate-mediated EMT processes through the activation of ADAM10 and ADAM17 in colon cancer cells. PMID: 27837433
  39. Studies demonstrate a role for ADAM10 in the ectodomain shedding of LRP1 in the brain and the clearance of Abeta across the blood-brain barrier, which may provide a novel strategy for attenuating Abeta accumulation in the AD brain PMID: 27503326
  40. In response to trastuzumab, both HER3 and the metalloprotease ADAM10 are simultaneously upregulated. The proteolytic activity of the latter then releases the HER3 ligand heregulin from the cell surface to activate HER3 and confer resistance to trastuzumab by inducing compensatory growth factor receptor signaling. PMID: 26863569
  41. Active ADAM10 promotes the carcinogenesis, invasion, metastasis and proliferation of ESCC and controls invasion and metastasis at least in part through the shedding of E-cadherin activity. PMID: 26986985
  42. We now show that ADAM10 is critical for alpha-hemolysin-mediated activation of the NLRP3 inflammasome in human monocytes as siRNA knockdown or chemical blockade of ADAM10-alpha-hemolysin interaction leads to diminished inflammasome activation and cell death by reducing the available ADAM10 on the cell surface. PMID: 27043625
  43. ADAM10 was overexpressed in the posterior band of sections from some patients with temporomandibular joint disk disorders. PMID: 26947053
  44. ADAM10 activity contributes to house dust mite-induced shedding of chemokines, including CCL20 PMID: 26296735
  45. The results of this study demonistrated that age-dependent increase in ADAM10 levels and activity in platelets. PMID: 26757187
  46. higher expression levels in the allergic nasal mucosa PMID: 26250527
  47. The production of ADAM10-positive microvesicles from smoke-exposed neutrophils provides a novel molecular mechanism for the vastly accelerated risk of AAA in smokers. PMID: 26422658
  48. activated microRNA-494-targets Bmi1 and ADAM10 by silibinin and ablates cancer stemness in head and neck squamous cell carcinomas PMID: 26090866
  49. These findings indicate that different mechanisms regulate shear- and ligand-induced shedding and shear forces found within the vasculature can regulate ADAM10 activity. PMID: 26840909
  50. Data suggest that large extracellular loop of Tspan14 mediates interaction with ADAM10, promotes ADAM10 maturation/trafficking to cell surface, and affects ADAM10 substrate specificity; ADAM10/Tspan14 interact in platelets/vascular endothelial cells. PMID: 26668317

Show More

Hide All

Involvement in disease
Reticulate acropigmentation of Kitamura (RAK); Alzheimer disease 18 (AD18)
Subcellular Location
Cell membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Cytoplasmic vesicle, clathrin-coated vesicle. Cell projection, axon. Cell projection, dendrite. Cell junction, adherens junction. Cytoplasm.
Tissue Specificity
Expressed in the brain (at protein level). Expressed in spleen, lymph node, thymus, peripheral blood leukocyte, bone marrow, cartilage, chondrocytes and fetal liver.
Database Links

HGNC: 188

OMIM: 602192

KEGG: hsa:102

STRING: 9606.ENSP00000260408

UniGene: Hs.172028

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1